NEW YORK, Nov. 4 (Xinhua) -- Pfizer on Tuesday reported third-quarter revenues of 16.7 billion U.S. dollars, representing a 7 percent operational decline year over year.
Reported diluted earnings per share were 0.62 dollars, while adjusted diluted earnings per share were 0.87 dollars.
The company reaffirmed its full-year 2025 revenue guidance in a range of 61 billion to 64 billion dollars and raised its adjusted diluted earnings per share outlook to between 3 and 3.15 dollars.
"I am proud of Pfizer's leadership as the first in our industry to reach an agreement with the U.S. Government, which we believe provides greater clarity for our business," said Albert Bourla, chairman and CEO of Pfizer.
"Additionally, our recent strategic actions have strengthened opportunities to advance innovation that could address significant medical needs in high growth markets, helping us deliver value for patients and shareholders," he said. ■